The average, or consensus price target of the brokerages polled by Zacks Research, stands at $252.818. The company’s shares closed last Friday at $177.56. It has 72.68 P/E ratio. The 50-Day Moving Average price is $203.20 and the 200 Day Moving Average price is recorded at $222.59.Valeant Pharmaceuticals global, Inc. Valeant Pharmaceuticals Intl has a 12-month low of $120.12 and a 12-month high of $263.81.
Advertisement
Valeant Pharmaceuticals Intl (NYSE:VRX) last announced its quarterly earnings results on Thursday, July 23rd.
Looking ahead to future earnings growth, analysts are expecting Turkcell Iletisim Hizmetleri AS (NYSE:TKC) to report earnings per share of $N/A for the quarter ending on 2015-09-30. The company issued revenue guidance of $3.25-3.45 billion, compared to the consensus revenue estimate of $3.32 billion.
Salix added $461 million in third-quarter revenue and represented about 17% of the top line.
The company also hiked its estimate for cash earnings – or adjusted profit – to $11.67-$11.87 per share from $11.50-$11.80 per share. Three months ago analysts had a rating of 1.83 on the stock. The company, known for gobbling up smaller drugmakers to get their products and then slashing jobs and research programs, jacked up the drugs’ prices shortly after buying them from Marathon Pharmaceuticals in February, tripling one and raising the other sixfold.
We rate VALEANT PHARMACEUTICALS INTL (VRX) a HOLD. Guggenheim reiterated a buy rating and set a $300.00 price target on shares of Valeant Pharmaceuticals Intl in a report on Friday, July 17th. Six research analysts have rated the stock with a hold rating and twenty-one have given a buy rating to the company’s stock. The company now has an average rating of Buy and a consensus price target of $238.12.
The New York-based fund Pershing Square Capital Management L.P. revealed it had purchased so far a stake worth about 29.95% of the investment manager’s stock portfolio in Valeant Pharmaceuticals Intl. Excluding items, the company’s cash earnings climbed to $2.74 per share from $2.11 per share. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.
Advertisement
Valeant Pharmaceuticals global, Inc.is a specialty pharmaceutical and medical device business. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: developed markets and emerging markets. The Company’s Emerging Markets segment includes OTC products and branded pharmaceuticals, branded generic pharmaceutical products, and medical device products.
